Introduction
============

Gastric cancer (GC) is a malignant tumor that originates in the epithelium of the gastric mucosa and is one of the most common types of malignant tumors in the world ([@b1-br-0-0-1281]). According to GLOBOCAN 2018, there were \>1,000,000 new cases of GC and \~783,000 deaths in 2018, thus making it the cancer type with the fifth highest incidence rate and the third highest mortality in the world ([@b2-br-0-0-1281]). The poor five-year survival rate of GC is primarily due the advanced stage of gastric tumors at the initial diagnosis in the majority of patients, and thus limits treatment opportunities ([@b3-br-0-0-1281]). According to the Cancer Staging Manual, 8th edition, of the American Joint Committee on Cancer, only 30% of GC cases are diagnosed prior to metastasis, and the five-year survival for pathological Tumor-Node-Metastasis stage groups are between 68-80% for stage I, 46-60% for stage II, 8-30% for stage III and 5% for stage IV ([@b4-br-0-0-1281]). Therefore, identifying potential biomarkers for patients with early GC is critical for improving patient outcomes.

In recent years, a variety of bioinformatics methods have contributed greatly to the discovery of biomarkers associated with tumor development, diagnosis and prognosis ([@b5-br-0-0-1281]). The combined use of multiple databases of biological information for the analysis of cancer has also yielded certain breakthroughs. Yong *et al* ([@b9-br-0-0-1281]) used Gene Expression Omnibus (GEO), Oncomine, Search Tool for Recurring Instances of Neighbouring Genes (STRING) and other databases for bioinformatic analysis, and concluded that *PPP2CA* may function as an oncogene and a prognostic biomarker or therapeutic target in the progression of colorectal cancer. Troiano *et al* ([@b10-br-0-0-1281]) used the GEO database and Oncomine to examine the expression of *BIRC5*/Survivin in oral squamous cell carcinoma and showed that Survivin expression was upregulated compared with non-cancerous tissue. In addition, immunohistochemistry staining showed that cytoplasmic expression of Survivin was associated with poor overall survival in patients with oral squamous cell carcinoma. It may be beneficial to use multiple datasets and analysis tools to determine the potential mechanisms underlying development and progression of GC, and to identify potentially novel and specific diagnostic biomarkers for early detection of GC to improve the survival of patients.

In the present study, the expression profiles from four datasets (GSE13911, GSE19826, GSE54129 and GSE118916) in human GC and normal gastric tissue samples were obtained from the GEO database and analyzed to identify differentially expressed genes (DEGs). Gene Ontology (GO) and pathway enrichment analysis were performed to identify the biological functions and pathways of the DEGs. STRING and Cytoscape were used to construct a protein-protein interaction (PPI) network, and a total of six key genes were selected from the PPI network and DEGs. The value of the key genes was validated using the Oncomine and Kaplan-Meier platforms to further increase the reliability of the results and confirm the prognostic value of the key genes.

Materials and methods
=====================

### Microarray data

The key word 'gastric cancer' was searched in the GEO database ([ncbi.nlm.nih.gov/geo/](ncbi.nlm.nih.gov/geo/)), and a total of 9,224 datasets on human GC were retrieved. In the present study, four gene expression profiles from the GEO database were used, as they have not been studied together previously. The four datasets were: GSE13911([@b11-br-0-0-1281]), GSE19826([@b12-br-0-0-1281]), GSE54129 and GSE118916([@b13-br-0-0-1281]). Among these, GSE13911, GSE19826 and GSE54129 were based on the GPL570 platform \[(HG-U133_Plus_2) Affymetrix Human Genome U133 Plus 2.0 Array\]. GSE118916 was based on the GPL15207 platform \[(PrimeView) Affymetrix Human Gene Expression Array\].

### Identification of DEGs

DEGs between GC samples and normal controls were identified using the GEO2R online analysis tool ([ncbi.nlm.nih.gov/geo/geo2r](ncbi.nlm.nih.gov/geo/geo2r)); \|log FC\|≥1.0 and corrected P\<0.05 were used as the cutoff criteria. The common DEGs of the four gene expression profiles were screened using Wayne analysis in Funrich ([funrich.org/](funrich.org/)).

### GO and KEGG enrichment analyses of DEGs

After obtaining the common DEGs, GO ([@b14-br-0-0-1281],[@b15-br-0-0-1281]) and KEGG ([@b16-br-0-0-1281]) analyses of the DEGs were performed using the Database for Annotation Visualization and Integrated Discovery (DAVID) online tool ([@b17-br-0-0-1281],[@b18-br-0-0-1281]), with P\<0.01 used as the threshold for significance. GO was used to identify the enrichment functions of three independent categories of genes; biological process (BP), cellular component (CC) and molecular function (MF). KEGG was used to search for the pathways associated with the identified genes ([@b19-br-0-0-1281]). Only the top 10 BP, CC and MF terms, and the KEGG pathway with the smallest P-value were selected for further examination in the present study. The figures were generated using the OmicShare tools (omicshare.com/tools), a free online platform for data analysis.

### PPI network construction

To explore the interaction between DEGs, the DEGs were analyzed using STRING ([@b20-br-0-0-1281]) to generate a PPI network. PPI pairs with a combined score \>0.4 were extracted, and disconnected nodes in the network were hidden. Subsequently, the PPI network was visualized using Cytoscape ([@b21-br-0-0-1281]) and the degree of each protein node was calculated using the cytoHubba ([@b22-br-0-0-1281]) plug-in in Cytoscape.

### Identification of key genes

The two genes with the highest degree of connectivity in the PPI network, the two genes with the largest logFC values and the two genes with the smallest logFC among the shared DEGs were selected and considered key genes.

### Analysis of key genes in Oncomine

The Oncomine database ([oncomine.org/](oncomine.org/)) was used to explore the mRNA expression differences of six key genes between GC and normal gastric tissue. Oncomine is a chip-based gene database and integrated data mining online cancer microarray database designed to facilitate the discovery of novel biomarkers from genome-wide expression analysis ([@b23-br-0-0-1281]).

### Survival analysis of key genes

The Kaplan-Meier plotter ([@b24-br-0-0-1281]) is an online tool that can assess the effect of 54,000 genes on survival in 21 types of cancer. The largest datasets include breast (n=6,234), ovarian (n=2,190), lung (n=3,452) and gastric cancer (n=1,440) cancer. The primary purpose of the tool is to discover and validate biomarkers for survival. Online survival analysis of the selected key genes based on the GC database was performed using Kaplan-Meier Plotter. The hazard ratio (HR) with 95% confidence intervals (CIs) and log-rank P-values were calculated.

Results
=======

### Identification of DEGs

GSE13911 includes 38 GC samples and 31 normal samples, GSE19826 contains 12 GC samples and 15 normal samples, GSE54129 contains 111 GC samples and 21 normal samples, and GSE118916 contains 15 GC samples and 15 normal samples ([Table I](#tI-br-0-0-1281){ref-type="table"}). In GSE13911, there are 26 intestinal, 4 mixed, 6 diffuse and 2 unclassified gastric carcinoma tissues, as well as 31 normal adjacent tissues. Unfortunately, information on the histological subtypes were not available in the other datasets. In the datasets, 1,001 upregulated and 2,304 downregulated DEGs were identified in GSE13911, 407 upregulated and 753 downregulated DEGs were identified in GSE19826, 1,852 upregulated and 2,083 downregulated DEGs were identified in GSE54129, and 977 upregulated and 903 downregulated DEGs were identified in GSE118916. Wayne analysis identified 99 common upregulated genes and 172 common downregulated genes were obtained from the 4 datasets ([Table II](#tII-br-0-0-1281){ref-type="table"}; [Fig. 1](#f1-br-0-0-1281){ref-type="fig"}).

### GO and KEGG pathway enrichment analyses of DEGs

GO and KEGG pathway enrichment analyses of the DEGs was performed using the online tool DAVID, and the results are presented in [Table III](#tIII-br-0-0-1281){ref-type="table"}. GO analysis showed that in BP, the DEGs were primarily enriched for the GO terms: 'extracellular matrix organization', 'collagen catabolic process', 'cell adhesion', 'collagen fibril organization' and 'digestion' ([Table III](#tIII-br-0-0-1281){ref-type="table"}; [Fig. 2A](#f2-br-0-0-1281){ref-type="fig"}). CC analysis revealed that the DEGs were significantly enriched for the terms: 'extracellular space', 'extracellular matrix', 'extracellular exosome', 'extracellular region' and 'endoplasmic reticulum lumen' ([Table III](#tIII-br-0-0-1281){ref-type="table"}; [Fig. 2B](#f2-br-0-0-1281){ref-type="fig"}). For MF, the DEGs were enriched for the GO terms: 'platelet-derived growth factor binding', 'collagen binding', 'extracellular matrix binding', 'inward rectifier potassium channel activity' and 'SMAD binding' ([Table III](#tIII-br-0-0-1281){ref-type="table"}; [Fig. 2C](#f2-br-0-0-1281){ref-type="fig"}). According to KEGG pathway analysis, the DEGs were primarily enriched for the pathway terms: 'ECM-receptor interaction', 'protein digestion and absorption', 'focal adhesion', 'amoebiasis' and 'gastric acid secretion' ([Table III](#tIII-br-0-0-1281){ref-type="table"}; [Fig. 2D](#f2-br-0-0-1281){ref-type="fig"}).

### PPI network construction

Based on the STRING prediction results, a PPI network with 211 nodes and 741 sides was constructed in Cytoscape ([Fig. 3](#f3-br-0-0-1281){ref-type="fig"}), and the number of segments connected to each gene in the figure represents its degree.

### Identification of six key genes

The two genes with the most nodes were *FN1* and *COL1A1*. In the PPI network, *FN1* was the most prominent, with the highest degree of connectivity at 52. The degree of connectivity of *COL1A1* is 43 ([Table IV](#tIV-br-0-0-1281){ref-type="table"}). Expression of these two genes is upregulated in GC tissues. Additionally, of those DEGs shared among the four gene expression profiles, the two DEGs with the largest logFC and the two DEGs with the smallest logFC values were selected. The higher the logFC in the upregulated DEGs, the greater the increase in expression of the gene. Similarly, the lower the logFC values in the downregulated DEGs, the greater the decrease in expression of the gene. When sorting DEGs according to logFC, the logFC of GSE19826 was used as the standard, as chip GSE19826 represented a homogenous cancer tissue population at each Tumor-Node-Metastasis stage ([@b25-br-0-0-1281]), which increases the accuracy of the expression profile ([Table V](#tV-br-0-0-1281){ref-type="table"}). The two DEGs with the largest logFC values were *INHBA* (logFC=4.35) and *CST1* (logFC=4.18) ([Table VI](#tVI-br-0-0-1281){ref-type="table"}). The two DEGs with the smallest logFC values were *ATP4A* (logFC=-6.46) and *ATP4B* (logFC=-5.91) ([Table VII](#tVII-br-0-0-1281){ref-type="table"}). Therefore, these six genes were selected as key genes.

### Analysis of the six key genes in Oncomine

The Oncomine database was used to confirm the expression of the six key genes in 20 different types of cancer. The results showed that there were statistically significant differences in their expression. In the Oncomine database, there were no studies showing low expression of *FN1*, *COL1A1*, *INHBA* or *CST1* in GC, but there were six, eight, seven and four studies showing increased expression, respectively. For *ATP4A* and *ATP4B*, the reverse was observed with no studies showing high expression, but seven and six studies, respectively, showing decreased expression ([Fig. 4](#f4-br-0-0-1281){ref-type="fig"}).

After comparing the expression levels of these six genes in cancerous and normal gastric tissue, the expression levels of *FN1*, *COL1A1*, *INHBA* and *CST1* in GC tissues were significantly higher compared with the control group, and the expression levels of *ATP4A* and *ATP4B* in GC tissues were significantly lower compared with the control group ([Table VIII](#tVIII-br-0-0-1281){ref-type="table"}; [Fig. 5](#f5-br-0-0-1281){ref-type="fig"}).

In addition, meta-analyses of the six key genes in GC in the Oncomine database also supported the findings that expression of *FN1*, *COL1A1*, *INHBA* and *CST1* is upregulated in GC, whereas expression of *ATP4A* and *ATP4B* is downregulated in GC ([@b11-br-0-0-1281],[@b12-br-0-0-1281],[@b26-br-0-0-1281]). The studies and references involved are shown in [Fig. 6](#f6-br-0-0-1281){ref-type="fig"}. In the meta-analyses, P=-0.000, FC≥2.0 and gene rank ≤300 were selected as the cutoff criteria.

### Survival analysis of the six key genes

To identify the prognostic value of the six potential key genes, overall survival curves based on differential expression of the six key genes were plotted using Kaplan-Meier plotter ([Fig. 7](#f7-br-0-0-1281){ref-type="fig"}). There were 1,440 patients with GC on the Kaplan-Meier plotter platform who were suitable for the analysis of overall survival. The curves indicate that overexpression of the six key genes is significantly associated with decreased overall survival times of patients with GC. However, it is worth noting that *ATP4A* and *ATP4B* were significantly downregulated in GC samples in the present study.

Discussion
==========

GC is a complex heterogeneous disease with high incidence and mortality rates, and poses a serious threat to afflicted patients. Therefore, it is important to identify biomarkers that are meaningful for both diagnostic and prognostic assessment ([@b29-br-0-0-1281]).

In the present study, 271 DEGs were screened, including 99 upregulated and 172 downregulated genes, by analyzing four gene expression profiles containing a combined 176 GC tissue samples and 82 normal gastric tissue samples. Of the causes of cancer-associated deaths, 90% are the result of metastasis ([@b30-br-0-0-1281]). In the present study, GO enrichment results showed that the occurrence and development of GC was closely associated with metastasis. GO analysis indicated that DEGs were primarily associated with extracellular matrix organization, collagen catabolic process and cell adhesion. Collagen is the primary component of the extracellular matrix and of the interstitial microenvironment. Collagen can provide a scaffold for tumor cell growth and induce migration of tumor cells ([@b31-br-0-0-1281],[@b32-br-0-0-1281]). There is evidence that collagen synthesis increases in the presence of a gastric tumor ([@b33-br-0-0-1281]). Zhou *et al* ([@b32-br-0-0-1281]) reported that collagen components are quantitatively and qualitatively reorganized in the tumor microenvironment of GC, and collagen width was identified as a useful prognostic indicator for GC ([@b32-br-0-0-1281]). In addition, studies have shown that changes in cell-cell adhesion and cell-matrix adhesion can promote cancer cell metastasis ([@b34-br-0-0-1281]). MF analysis showed that the DEGs were significantly enriched in platelet-derived growth factor binding. It has been demonstrated that inhibition of platelet-derived growth factor receptor-a can reduce the proliferation of gastrointestinal stromal tumor cells with mutant v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) by affecting the KIT-dependent transcription factor ETV1([@b35-br-0-0-1281]).

KEGG pathway analysis showed that the DEGs were primarily enriched in ECM-receptor interaction, protein digestion and absorption, and focal adhesion. ECM-receptor interaction serves a vital role in several types of cancer ([@b36-br-0-0-1281]). The interaction between membrane receptors of tumor cells and ECM proteins serve an important role in tumor invasion and metastasis ([@b39-br-0-0-1281]), and ECM-receptor interaction serve a crucial role in the process of tumor shedding, adhesion, degradation, movement and hyperplasia ([@b38-br-0-0-1281]). In addition, the non-steroidal anti-inflammatory drug celecoxib may exhibit anti-GC effects by inhibiting the expression of various proteins and inhibiting leukocyte transendothelial migration and focal adhesion ([@b40-br-0-0-1281]), which provides a possible mechanism for future investigations of the role of focal adhesion in GC and developing new anti-GC drugs.

The degree of connectivity of a gene in a PPI network reflects its association with GC. The greater the connectivity, the closer a gene is to the disease mechanism. The logFC values of DEGs reflects the level of up or downregulation of the gene. The higher the logFC values in the upregulated DEGs, the greater the degree of upregulation of the gene, and the lower the logFC values in the downregulated DEGs, the greater the degree of downregulation ([@b41-br-0-0-1281]). Thus it was hypothesized that the DEGs with the highest and lowest logFC values would be the genes most closely associated with disease mechanisms.

In the present study, the two genes with the highest degree of connectivity in the PPI network, and the two DEGs with the largest and smallest logFC values, were all selected as key genes. These were *FN1*, *COL1A1*, *INHBA*, *CST1*, *ATP4A* and *ATP4B*. These six key genes were verified in the Oncomine database. Expression of *FN1*, *COL1A1*, *INHBA* and *CST1* were upregulated in GC, and expression of ATP4A and ATP4B were downregulated, consistent with the results obtained from analysis of the GEO datasets. Furthermore, survival analysis showed that upregulation of the six key genes was significantly associated with worse overall survival, and downregulation of ATP4A and ATP4B expression predicted a more favorable prognosis for patients with GC, providing novel insights into potential GC treatment strategies.

*FN1* was the gene with the highest degree of connectivity. It is expressed in a wide range of healthy plasmalemmas, lamina propria mucosae and smooth-muscle cell layers, and it is involved in a variety of cellular processes including embryogenesis, blood coagulation, wound healing, host defense and metastasis ([@b44-br-0-0-1281]). As a glycoprotein involved in cell adhesion and migratory processes, *FN1* is hypothesized to be associated with signaling pathways associated with cancer ([@b13-br-0-0-1281]). Expression of *FN1* is significantly increased in anti-chemotherapy osteosarcoma cell lines and tissues, and is associated with a poor prognosis ([@b45-br-0-0-1281]). Knockdown of *FN1* gene expression results in reduced cell proliferation, increased cellular senescence and apoptosis, and reduced migration and invasion, by blocking the activation of the PI3K/AKT signaling pathway ([@b46-br-0-0-1281]). Furthermore, downregulation of *FN1* inhibits proliferation, migration and invasion, and thus reduces progression of colorectal cancer ([@b47-br-0-0-1281]). The results of the present study suggest that *FN1* may be a potential biomarker and therapeutic target for diagnosis and treatment of GC, consistent with previous studies ([@b13-br-0-0-1281],[@b48-br-0-0-1281],[@b49-br-0-0-1281]), and thus further confirming the significance of *FN1* in GC.

COL1A1 is one of the most important components of the ECM, and it is highly expressed in most connective tissues and various human solid tumors ([@b50-br-0-0-1281]). It is also the primary component of type I collagen, which serves a key role in tumor cell adhesion and invasion ([@b51-br-0-0-1281]). A mechanistic study revealed that COL1A1 and COL1A2 affects angiogenesis in GC, and their expression is also significantly associated with progression of GC ([@b52-br-0-0-1281]). In addition, Zhang *et al* ([@b53-br-0-0-1281]) further confirmed that overexpression of *COL1A1* promoted GC cell proliferation *in vitro*. These previous studies support the use of *COL1A1* as a key potential GC biomarker in the present study.

*INHBA* is a member of the transforming growth factor-β (TGF-β) superfamily, which is closely associated with tumor proliferation and expression is upregulated in lung cancer ([@b54-br-0-0-1281]), GC ([@b12-br-0-0-1281]) and colon cancer ([@b55-br-0-0-1281]), where *INHBA* expression is closely associated with their prognosis. In a study of GC, Chen *et al* ([@b56-br-0-0-1281]) found that *INHBA* gene silencing reduced migration and invasion of GC cells by blocking the activation of the TGF-β signaling pathway. They suggested that *INHBA* was a potential target for GC therapy ([@b56-br-0-0-1281]). Another study showed that *INHBA* mRNA expression in GC may be a useful prognostic biomarker for patients with stage II or III GC who receive adjuvant chemotherapy with S-1([@b57-br-0-0-1281]). The results of the present study support the conclusions drawn in these previous studies.

Cystatin SN (*CST1*) is a member of the type 2 cystatin superfamily, the primary role of which is to limit the proteolytic activity of cysteine proteases ([@b58-br-0-0-1281]). The dysregulated expression of *CST1* is hypothesized to be involved in several types of cancer, including cholangiocarcinoma ([@b59-br-0-0-1281]), breast cancer ([@b58-br-0-0-1281]), GC ([@b60-br-0-0-1281]) and colorectal cancer ([@b61-br-0-0-1281]). *CST1* prevents cell aging and promotes cancer development by affecting the activity of cathepsin B ([@b62-br-0-0-1281]). However, *CST1* has not been analyzed using bioinformatics for survival prognosis in GC, to the best of our knowledge. Using multiple databases, the present study is the first to validate *CST1* as a novel prognostic biomarker and a potential therapeutic target for treatment of GC.

*ATP4A* encodes the α subunit and *ATP4B* encodes the β subunit of the gastric H+, K+-ATPase, respectively. They regulate gastric acid secretion and, as a result, are targets for acid reduction ([@b63-br-0-0-1281]). Fei *et al* ([@b64-br-0-0-1281]) found that expression of *ATP4A* and *ATP4B* were significantly downregulated in patients with GC, but their expression was not significantly correlated with overall survival ([@b64-br-0-0-1281]). In the present study, downregulation of *ATP4A* and *ATP4B* expression was associated with favorable overall survival in patients with GC. Downregulation of *ATP4A* and *ATP4B* mRNA expression in GC tissue is associated with the development of GC ([@b65-br-0-0-1281]). Correa\'s Cascade is inversely associated with gastric acid secretion rate, the downregulation of *ATP4A* and *ATP4B* mRNA expression begins in the early stages of gastric mucosal lesions, and the expression of both is gradually decreased as Correa\'s cascade progresses ([@b66-br-0-0-1281]). In addition, *Helicobacter pylori* (*H. pylori*) inhibits parietal acid secretion by downregulating the expression of *ATP4A* and *ATP4B* in gastric parietal cells prior to the formation of GC, suggesting that *H. pylori* is closely associated with the development of GC ([@b67-br-0-0-1281]). Thus, it was hypothesized that *ATP4A* and *ATP4B* may inhibit the formation of GC. Survival analysis showed that *ATP4A* and *ATP4B* in GC are adverse prognostic factors for patients with GC, suggesting that upregulation is associated with progression of GC. However, studies have reported that the expression of *ATP4A* and *ATP4B* is not regulated by *H. pylori* in GC ([@b68-br-0-0-1281]). Other studies have shown significant decreases in the abundance of *Helicobacter* and *Neisseria*, and significant increases in *Achromobacter*, *Citrobacter*, *Phyllobacterium*, *Clostridium*, *Rhodococcus* and *Lactobacillus* in gastric carcinoma in comparison with chronic gastritis ([@b71-br-0-0-1281],[@b72-br-0-0-1281]). Additionally, the gastric microbiota composition in patients with gastric carcinoma is significantly different compared with patients with chronic gastritis ([@b71-br-0-0-1281]). Therefore, it was hypothesized that the formation of an altered gastric microbiota composition may result in the expression of *ATP4A* and *ATP4B* to be passively upregulated as GC progresses. Further research is required to more accurately determine the biological function of *ATP4A* and *ATP4B* in GC.

Although several genes were identified as promising diagnostic and prognostic biomarkers for GC, the present study has the following limitations. First, the present study lacked experimental and clinical validation. Second, the possibility that different histological types may affect the accuracy of results cannot be eliminated. Thus, future bioinformatics analysis should be designed such that samples can be stratified by histological type. Finally, the sample size was relatively small for the RNA-Seq experiments, which may result in inaccuracies or results which are not completely representative of the wider populace. Therefore, it is necessary to use larger samples to perform bioinformatics analysis, and further experimental and clinical studies are required.

In conclusion, the present study used bioinformatics to analyze biological processes and signaling pathways closely associated with GC occurrence and development and identified *FN1*, *COL1A1*, *INHBA* and *CST1* as promising diagnostic and prognostic biomarkers for GC patients. Additionally, the results of the survival analysis of *ATP4A* and *ATP4B* were inconsistent with other international studies. Therefore, further studies are required to assess the effects of *ATP4A* and *ATP4B* on GC initiation and development. Furthermore, experimental and clinical studies are required to validate the findings of the present study and determine the potential clinical value of these potential biomarkers.
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![Protein-protein interaction network of differentially expressed genes. Red indicates upregulated genes, and green represents downregulated genes.](br-12-04-0178-g02){#f3-br-0-0-1281}
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![Expression of six key genes in different gastric cancer gene chips in Oncomine. P\<0.0001 and a \|fold change\|\>2 were used as the threshold. Comparison of mRNA expression in cancerous vs. normal gastric tissue. (A) *FN1*, (B) *COL1A1*, (C) *INHBA*, (D) *CST1*, (E) *ATP4A* and (F) *ATP4B*.](br-12-04-0178-g04){#f5-br-0-0-1281}
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###### 

Information for four gene expression profiles from Gene Expression Omnibus.

  Dataset ID   Gastric cancer   Normal   Total Number   Platform
  ------------ ---------------- -------- -------------- ----------
  GSE13911     38               31       69             GPL570
  GSE19826     12               15       27             GPL570
  GSE54129     111              21       132            GPL570
  GSE118916    15               15       30             GPL15207

###### 

The differentially expressed genes identified from the four gene expression profiles, between gastric cancer and normal tissues.

  Differentially expressed genes   Gene terms
  -------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Upregulated                      INHBA CST1 COL11A1 FAP COL10A1 FNDC1 COL8A1 SERPINH1 CDH3 THBS2 CLDN1 TNFRSF11B SPP1 COL1A2 SFRP4 SULF1 CPXM1 BMP1 MFAP2 COL1A1 CTHRC1 BGN RARRES1 IGF2BP3 THBS4 COL6A3 SRPX2 OSR2 HOXB7 TIMP1 ASPN THY1 FKBP10 PRRX1 SDS APOE PMEPA1 COL12A1 GPNMB FBN1 ADAM12 C3 APOC1 COL5A1 SPARC EPHB2 NID2 CMTM3 PLEKHO1 TNFRSF10B EHD2 FN1 MMP11 COCH AMIGO2 COL5A2 OLFML2B KLHL23 SPOCK1 CDH11 TWIST1 RAB31 SULF2 FGD6 VCAN ITGBL1 PCOLCE HAVCR2 THBS1 DNM1 IGFBP7 PLAU TMEM158 COL3A1 FLNA EDNRA LEF1 LIPG FZD2 GXYLT2 S100A10 LGALS1 NRP2 SIRPA ANTXR1 CD9 LIF COL4A2 TGM2 COL6A1 PDPN KCNJ8 ACTN1 GPR161 ZAK RCN3 BAG2 BHLHE40 COL4A1
  Downregulated                    ATP4A ATP4B KCNE2 AQP4 GIF LIPF GKN1 GKN2 DPCR1 PGC SOSTDC1 ESRRG MUC6 SST FBP2 CPA2 VSIG1 CXCL17 PDIA2 CCKBR TMED6 CHGA TFF2 PSCA FUT9 CA9 SCNN1G GUCA2B C16orf89 SLC26A9 KLK11 CWH43 DNER PSAPL1 CNTN3 ALDH3A1 GATA5 SCGB2A1 UGT2B15 RDH12 CLIC6 NRG4 CLDN18 CAPN9 SLC16A7 SSTR1 FBXL13 TCN1 VSIG2 AKR1B10 B3GNT6 FOLR1 MUM1L1 CHGB MAL TRIM50 AKR7A3 KIAA1324 PAIP2B SULT2A1 PTPRZ1 ARX LIFR ALDH1A1 HYAL1 BEX5 CA2 CYP2C18 ME1 SCNN1B ADH7 GCNT2 ACER2 FMO5 HPGD RASSF6 TFF1 TMEM171 CA4 KCNJ16 LDHD KCNJ15 GABRB3 HOMER2 TMPRSS2 LYPD6B KLHDC7A ARHGAP42 PLAC8 IGFBP2 CAPN13 SYTL5 PDGFD RNASE1 RORC CYP2C9 EPN3 PBLD METTL7A ZBTB7C UBL3 SH3RF2 RNASE4 ARHGEF37 ALDH6A1 RAB27B SULT1B1 PKIB PXMP2 GPRC5C RIMBP2 ATP8A1 FAM20A PIGR GOLM1 CYP3A5 FAM46C C9orf152 COBLL1 FA2H SORBS2 DGKD SGK2 TMEM220 ANG PLLP MYCN C1orf116 FGD4 SLC41A2 ADAM28 MAGI1 GRAMD1C IQGAP2 GULP1 SYTL2 DHRS7 OASL RNF128 DBT ELL2 RAB27A NOSTRIN NEDD4L PPFIBP2 AKR1C3 PELI2 SMPD3 PTPRN2 RASEF TMEM92 ABCC5 GALNT12 LMO4 NTN4 TMEM116 ID4 ELOVL6 ALDOB EPB41L4B CD36 GALNT5 SH3BGRL2 MAGI3 MICALL1 HIPK2 MAOA WWC1 SLC7A8 CDC14B FAM107B SUCLG2

Upregulated genes are listed from largest to smallest fold change values. Downregulated genes are listed from smallest to largest fold change values.

###### 

GO term and KEGG pathway enrichment analyses of the 271 differentially expressed genes.

  Category       Term         Description                                                                  Count   P-Value
  -------------- ------------ ---------------------------------------------------------------------------- ------- --------------
  BP term        GO:0030198   Extracellular matrix organization                                            23      1.28x10^-13^
  BP term        GO:0030574   Collagen catabolic process                                                   14      7.06x10^-12^
  BP term        GO:0007155   cell adhesion                                                                30      3.59x10^-11^
  BP term        GO:0030199   Collagen fibril organization                                                 9       7.87x10^-08^
  BP term        GO:0007586   Digestion                                                                    10      3.19x10^-07^
  BP term        GO:0035987   Endodermal cell differentiation                                              7       2.13x10^-06^
  BP term        GO:0001501   Skeletal system development                                                  11      3.42x10^-05^
  BP term        GO:0008202   Steroid metabolic process                                                    7       3.60x10^-05^
  BP term        GO:0071230   Cellular response to amino acid stimulus                                     7       6.04x10^-05^
  BP term        GO:0006805   Xenobiotic metabolic process                                                 8       1.45x10^-04^
  BP term        GO:0042060   Wound healing                                                                8       1.70x10^-04^
  BP term        GO:0006081   Cellular aldehyde metabolic process                                          4       4.70x10^-04^
  BP term        GO:0030277   Maintenance of gastrointestinal epithelium                                   4       6.20x10^-04^
  BP term        GO:0010107   Potassium ion import                                                         5       6.98x10^-04^
  BP term        GO:0007584   Response to nutrient                                                         7       7.50x10^-04^
  BP term        GO:0002576   Platelet degranulation                                                       8       7.99x10^-04^
  BP term        GO:0060021   Palate development                                                           7       8.64x10^-04^
  BP term        GO:0010812   Negative regulation of cell-substrate adhesion                               4       0.001003
  BP term        GO:0001503   Ossification                                                                 7       0.001131
  BP term        GO:0030168   Platelet activation                                                          8       0.001523
  BP term        GO:0051216   Cartilage development                                                        6       0.001703
  BP term        GO:0010628   Positive regulation of gene expression                                       12      0.001721
  BP term        GO:0001523   Retinoid metabolic process                                                   6       0.001977
  BP term        GO:0016525   Negative regulation of angiogenesis                                          6       0.002125
  BP term        GO:0055114   Oxidation-reduction process                                                  19      0.002857
  BP term        GO:0032964   Collagen biosynthetic process                                                3       0.003084
  BP term        GO:0008284   Positive regulation of cell proliferation                                    16      0.003752
  BP term        GO:0001649   Osteoblast differentiation                                                   7       0.004274
  BP term        GO:0022617   Extracellular matrix disassembly                                             6       0.005144
  BP term        GO:0071711   Basement membrane organization                                               3       0.005647
  BP term        GO:0050891   Multicellular organismal water homeostasis                                   3       0.005647
  BP term        GO:0001525   Angiogenesis                                                                 10      0.005716
  BP term        GO:0042476   Odontogenesis                                                                4       0.007007
  BP term        GO:0010575   Positive regulation of vascular endothelial growth factor production         4       0.007007
  BP term        GO:0050909   Sensory perception of taste                                                  4       0.008568
  BP term        GO:0001937   Negative regulation of endothelial cell proliferation                        4       0.008568
  BP term        GO:0040037   Negative regulation of fibroblast growth factor receptor signaling pathway   3       0.008901
  BP term        GO:0042572   Retinol metabolic process                                                    4       0.009418
  CC term        GO:0005615   Extracellular space                                                          63      9.65x10^-17^
  CC term        GO:0031012   Extracellular matrix                                                         28      2.46x10^-14^
  CC term        GO:0070062   Extracellular exosome                                                        87      1.68x10^-12^
  CC term        GO:0005576   Extracellular region                                                         61      4.86x10^-12^
  CC term        GO:0005788   Endoplasmic reticulum lumen                                                  20      4.73x10^-11^
  CC term        GO:0005581   Collagen trimer                                                              15      5.56x10^-11^
  CC term        GO:0005604   Basement membrane                                                            9       1.82x10^-05^
  CC term        GO:0005578   Proteinaceous extracellular matrix                                           22      3.57x10^-10^
  CC term        GO:0016324   Apical plasma membrane                                                       16      2.29x10^-05^
  CC term        GO:0009986   Cell surface                                                                 20      3.51x10^-04^
  CC term        GO:0005887   Integral component of plasma membrane                                        34      0.004256
  CC term        GO:0005886   Plasma membrane                                                              79      0.004569
  CC term        GO:0030141   Secretory granule                                                            6       0.004319
  CC term        GO:0031093   Platelet alpha granule lumen                                                 5       0.008125
  CC term        GO:0031090   Organelle membrane                                                           6       0.008522
  MF term        GO:0048407   Platelet-derived growth factor binding                                       6       2.55x10^-07^
  MF term        GO:0005518   Collagen binding                                                             8       2.37x10^-05^
  MF term        GO:0050840   Extracellular matrix binding                                                 6       3.05x10^-05^
  MF term        GO:0005242   Inward rectifier potassium channel activity                                  4       0.002802
  MF term        GO:0046332   SMAD binding                                                                 5       0.003328
  MF term        GO:0005201   Extracellular matrix structural constituent                                  12      2.77x10^-09^
  MF term        GO:0001758   Retinal dehydrogenase activity                                               3       0.004132
  MF term        GO:0005178   Integrin binding                                                             11      2.77x10^-06^
  MF term        GO:0005509   Calcium ion binding                                                          27      1.47x10^-05^
  MF term        GO:0008201   Heparin binding                                                              12      2.07x10^-05^
  MF term        GO:0016491   Oxidoreductase activity                                                      9       0.008547
  MF term        GO:0008083   Growth factor activity                                                       8       0.009105
  KEGG pathway   hsa04512     ECM-receptor interaction                                                     16      5.16x10^-11^
  KEGG pathway   hsa04974     Protein digestion and absorption                                             14      7.73x10^-09^
  KEGG pathway   hsa04510     Focal adhesion                                                               18      2.67x10^-07^
  KEGG pathway   hsa05146     Amoebiasis                                                                   10      1.63x10^-04^
  KEGG pathway   hsa04971     Gastric acid secretion                                                       8       4.23x10^-04^
  KEGG pathway   hsa04151     PI3K-Akt signaling pathway                                                   17      7.35x10^-04^
  KEGG pathway   hsa00830     Retinol metabolism                                                           7       0.00124
  KEGG pathway   hsa00982     Drug metabolism-cytochrome P450                                              7       0.001703
  KEGG pathway   hsa00980     Metabolism of xenobiotics by cytochrome P450                                 7       0.002628
  KEGG pathway   hsa05204     Chemical carcinogenesis                                                      7       0.003889

GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; BP, biological processes; CC, cellular component; MF, molecular function.

###### 

The 10 genes with the largest degree of connectivity in the protein-protein-interaction network.

  Rank   Gene     Degree
  ------ -------- --------
  1      FN1      52
  2      COL1A1   43
  3      COL1A2   38
  4      COL3A1   37
  5      FBN1     35
  6      BGN      32
  6      COL5A2   32
  8      TIMP1    31
  9      SPARC    30
  10     THBS2    28

###### 

The expression data from GSE19826 in gastric cancer.

  Tissue type             Accession no.   Title           Stage
  ----------------------- --------------- --------------- -------
  Noncancer tissue        GSM495051       CB2008210-1N    n/a
  Gastric cancer tissue   GSM495052       CB2008210-1T    II
  Noncancer tissue        GSM495053       CB2008210-2N    n/a
  Gastric cancer tissue   GSM495054       CB2008210-2T    IV
  Noncancer tissue        GSM495055       CB2008210-3N    n/a
  Gastric cancer tissue   GSM495056       CB2008210-3T    I
  Noncancer tissue        GSM495057       CB2008210-4N    n/a
  Gastric cancer tissue   GSM495058       CB2008210-4T    II
  Noncancer tissue        GSM495059       CB2008210-5N    n/a
  Gastric cancer tissue   GSM495060       CB2008210-5T    III
  Noncancer tissue        GSM495061       CB2008210-6N    n/a
  Gastric cancer tissue   GSM495062       CB2008210-6T    IV
  Noncancer tissue        GSM495063       CB2008210-7N    n/a
  Gastric cancer tissue   GSM495064       CB2008210-7T    IV
  Noncancer tissue        GSM495065       CB2008210-9N    n/a
  Gastric cancer tissue   GSM495066       CB2008210-9T    III
  Noncancer tissue        GSM495067       CB2008210-12N   n/a
  Gastric cancer tissue   GSM495068       CB2008210-12T   II
  Noncancer tissue        GSM495069       CB2008210-13N   n/a
  Gastric cancer tissue   GSM495070       CB2008210-13T   I
  Noncancer tissue        GSM495071       CB2008210-14N   n/a
  Gastric cancer tissue   GSM495072       CB2008210-14T   III
  Noncancer tissue        GSM495073       CB2008210-15N   n/a
  Gastric cancer tissue   GSM495074       CB2008210-15T   I
  Normal gastric tissue   GSM495075       CB2008210-3C    n/a
  Normal gastric tissue   GSM495076       CB2008210-5C    n/a
  Normal gastric tissue   GSM495077       CB2008210-9C    n/a

###### 

The 10 genes with the largest logFC values in GSE19826.

  Rank   Name       LogFC
  ------ ---------- -------
  1      INHBA      4.35
  2      CST1       4.18
  3      COL11A1    4.11
  4      FAP        3.91
  5      COL10A1    3.72
  6      FNDC1      3.27
  6      COL8A1     3.17
  8      SERPINH1   2.97
  9      CDH3       2.95
  10     THBS2      2.94

FC, fold change.

###### 

The 10 genes with the smallest logFC values in GSE19826.

  Rank   Name    LogFC
  ------ ------- -------
  1      ATP4A   -6.46
  2      ATP4B   -5.91
  3      KCNE2   -5.88
  4      AQP4    -5.81
  5      GIF     -5.75
  6      LIPF    -5.53
  6      CHIA    -5.51
  8      GKN1    -5.49
  9      GKN2    -5.44
  10     DPCR1   -4.83

FC, fold change.

###### 

Additional information for the six key genes shown in [Figure 5](#f5-br-0-0-1281){ref-type="fig"}.

  Author, year              Gene     Normal tissue samples   Gastric cancer samples   P-value        Fold Change   Published journal               (Refs.)
  ------------------------- -------- ----------------------- ------------------------ -------------- ------------- ------------------------------- ----------------------
  Chen *et al*, 2003        FN1      28                      8                        5.73x10^-14^   7.441         Molecular Biology of The Cell   ([@b26-br-0-0-1281])
  Cui *et al*, 2011         COL1A1   80                      80                       1.81x10^-15^   3.201         Nucleic Acids Research          ([@b28-br-0-0-1281])
  Cui *et al*, 2011         INHBA    80                      80                       5.17x10^-13^   3.043         Nucleic Acids Research          ([@b28-br-0-0-1281])
  Cho *et al*, 2011         CST1     19                      31                       3.17x10^-13^   21.525        Clinical Cancer Research        ([@b27-br-0-0-1281])
  Cho *et al*, 2011         ATP4A    19                      20                       4.73x10^-17^   -100.911      Clinical Cancer Research        ([@b27-br-0-0-1281])
  D\'Errico *et al*, 2009   ATP4B    31                      26                       6.15x10^-19^   -246.630      European Journal of Cancer      ([@b11-br-0-0-1281])
